Portfolio news - The Vaccine Group
Reach - a non-regulatory announcement
AIM: FIPP
13 December 2023
Frontier IP Group Plc
("Frontier IP" or the "Group")
Portfolio news - The Vaccine Group announces significant milestone in the appointment of Advisory Board
Frontier IP, a specialist in commercialising intellectual property, notes the following announcement that portfolio company The Vaccine Group ("TVG" or the "Company") has appointed an Advisory Board to support scale-up of the Company's novel herpesvirus-based vaccine platform.
The advisory board consists of three high-ranking veterinary experts with strong business experience and connections to major companies and other organisations in the animal health sector. The move reflects the progress TVG has made in establishing a strong vaccine pipeline.
Neil Crabb, Frontier IP Chief Executive Officer, said: "I am delighted TVG has been able to form an advisory group of such good quality. It is a testament to the potential of the Company, its vaccine platform and pipeline, and I look forward to further developments as TVG's vaccines move towards scale up and full commercialisation. "
The Vaccine Group statement begins:
The Vaccine Group announces appointment of Advisory Board
The Vaccine Group ("TVG") has appointed three high-ranking and well-connected animal health experts to form an advisory board to support scale up of the Company's novel herpesvirus-based vaccine platform and to forge deeper industry relationships.
TVG has made strong progress in establishing a pipeline of vaccines for use in livestock, pets and wildlife to tackle a range of viral and bacterial pathogens which cause severe economic harm or, if they are zoonotic, can also pose a threat to human health.
The advisory board members have extensive veterinary health and business experience. They are:
Christophe Barnier-Quer: Christophe works for Merck Life Science in its Contract Development and Manufacturing Organisations branch. He has a PhD in pharmaceutical science from Leiden University, an MBA from HEC Paris and 15 years' experience in vaccine R&D, including as R&D director for GALVmed.
Johan Dreesen: A doctor in veterinary medicine, Johann runs an animal health consultancy with a focus on start-ups, animal health pharmaceuticals and non-government organisations. He is a member of the Advisory Council to Kela Pharma and sits on the GALVmed board. He received his doctorate from Ghent University and worked in veterinary practice before leading businesses within Pfizer Animal Health and Zoetis.
Vaughn Kubiak: Vaughn has more than 40 years' experience in global animal health in a wide range of senior technical and managerial roles in major companies across R&D, quality assurance and quality control, regulatory affairs, product management and commercial operations. Before retirement in 2019, he spent 17 years at Zoetis. Vaughn now works as a consultant and sits on several technical advisory boards. He has a Master of Science degree in microbiology from Emory University and is involved in the Scientific Committee of the International Alliance for Biological Standardisation.
TVG has 12 vaccines currently under development targeting economically harmful and zoonotic diseases. They include vaccines for protection against porcine reproductive and respiratory syndrome, African swine fever, porcine circovirus-2, streptococcus suis, bovine respiratory syncytial virus and lumpy skin disease. TVG has also developed a transmissible candidate vaccine for Lassa fever for use in the rodent reservoir. All vaccines are based on the Company's tunable herpesvirus based platforms.
Jeremy Salt, Chief Executive of The Vaccine Group, said: "As we approach the end of another successful year for TVG, it is especially positive that we can look forward to gaining the support of three Board Advisors from January. Each of them brings great expertise in their own areas. This will be really helpful for TVG as we grow into a strong player in the global animal health innovation sector."
The Vaccine Group statement ends
ENQUIRIES
|
Frontier IP Group Plc |
T: 020 7332 2338 |
|
Neil Crabb, Chief Executive Officer Andrew Johnson, Communications and investor relations andrew.johnson@frontierip.co.uk Company website: www.frontierip.co.uk |
neil@frontierip.co.uk M: 07464 546 025 |
|
The Vaccine Group Jeremy Salt, Chief Executive Officer Allenby Capital Limited (Nominated Adviser) Nick Athanas / George Payne
|
jeremy.salt@thevaccinegroup.com T: 0203 328 5656
|
ABOUT THE VACCINE GROUP
The Vaccine Group (TVG) was founded in 2017 to develop and commercialise the recombinant vaccine technology work of Dr Michael Jarvis, Associate Professor in Virology and Immunology at the University of Plymouth's School of Biomedical Sciences.
Through a mixed funding model of public grants and private equity, TVG has established a pipeline of projects that address infectious diseases in animals that are either zoonotic, transferred from animals to humans, or have a serious commercial impact on livestock production, such as PRRS and African Swine Fever in pigs, and bovine tuberculosis in cattle.
Most emerging infections, especially those with high pandemic potential in humans, emerge from domestic and wildlife animal populations.
Due to the earlier ability to test animal vaccines in their intended host, and the relative speed at which animal compared to human vaccines are approved for use, vaccination of animals rather than humans is becoming accepted as an approach to protect humans against some emerging zoonotic pathogens.
Its business model is to develop vaccine candidates to proof-of-concept with commercial exploitation delivered through license agreements with vaccine manufacturing companies.
For more information: www.thevaccinegroup.com
About Reach announcements
This is a Reach announcement. Reach is an investor communication service aimed at assisting listed and unlisted (including AIM quoted) companies to distribute media only / non-regulatory news releases into the public domain. Information required to be notified under the AIM Rules for Companies, Market Abuse Regulation or other regulation would be disseminated as an RNS regulatory announcement and not on Reach.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
Latest directors dealings
- 7 hours ago Johnson Matthey
- 9 hours ago Galliford Try
- 9 hours ago Galliford Try
- 9 hours ago Centrica
- 10 hours ago Smith & Nephew